



Best of JAAD

DIRK M. ELSTON, MD

MEDICAL UNIVERSITY OF
SOUTH CAROLINA

CHARLESTON

NO CONFLICT OF INTEREST

Dupilumab associated with increased risk of MF

- ▶ Increased risk of CTCL in cohort of AD patients who used dupilumab (odds ratio 4.1003, 95% confidence interval 2.055-8.192)
- ▶ Risk persisted after exclusion of prior disease-modifying antirheumatic drug use
- ▶ Risk was not increased for other cutaneous or lymphoid malignancies
- ▶ Most (27/41) were diagnosed more than 1 year after dupilumab use
- ▶ [Volume 91, ISSUE 2, P255-258, August 2024](#)



Making sense of central centrifugal cicatricial alopecia

- ▶ Central alopecia in people of African descent is often multifactorial
- ▶ Black people get LPP, lupus and pattern alopecia just like everyone else
- ▶ With age, 50% of people of Northern European and African descent get pattern alopecia
- ▶ 50% of your scarring alopecia patients also have pattern alopecia
- ▶ [Volume 91, ISSUE 2, P243-245, August 2024](#)



Black or White: Consider the same range of entities as possible causes



Treat background pattern alopecia: Before and after oral minoxidil



Courtesy of Boni Elewski MD

Bimekizumab safety : liver

- ▶ 2186 patients over 2 years, hepatic events 3.5/100 patient years (PY) and did not increase from first to second year.
- ▶ 2-year ALT/AST elevations $>3x$ and $>5x$ the upper limit of normal were 2.3 and 0.6/100 PY
- ▶ Rates were similar to placebo, adalimumab, secukinumab, and Ustekinumab
- ▶ Volume 91, ISSUE 2, P281-289, August 2024



Trichophyton indotineae



- ▶ Highly contagious
- ▶ Widespread lesions resembling psoriasis
- ▶ Resistant to terbinafine
- ▶ Some success with prolonged intraconazole
- ▶ Volume 91, ISSUE 2, P315-323, August 2024



DRESS

- ▶ Median beta-lactam DRESS latency to be significantly shorter than that of vancomycin
- ▶ Cephalosporin and vancomycin cases had more severe courses with higher fatality and intensive care rates
- ▶ Although vancomycin DRESS often includes renal injury, in this study, liver injury was most common.

- ▶ Volume 90, ISSUE 6, P1240-1242, June 2024



Lentigo maligna/MMIS

- ▶ Melanoma in situ on the head and neck often requires margins >5 mm margins to achieve tumor clearance.
- ▶ When Mohs micrographic surgery is not possible, excision margins of ≥ 10 mm are likely necessary for head and neck tumors.

▶ Volume 90, ISSUE 6, P1226-1231, June 2024



Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab

High level of effectiveness

Favorable safety profile in patients with neoplasms

Acitretin and phototherapy recommended by
Psoriasis Foundation
Avoid TNFs



Safety profile of guselkumab with coexisting hepatitis B or C

Risk of HBV reactivation seems to be lower for guselkumab than other biologics

Monitor viral loads (ultraquantitative PCR quarterly)

Hep B: Avoid TNFs and Rituximab, other biologics and MTX lower risk

Hep C: TNFs preferred if biologic used

JAAD 2000; 90:1083-4



Risk of thromboembolism

- ▶ Lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases
- ▶ Retrospective, observational, comparative cohort study using US claims data
- ▶ Volume 90, ISSUE 5, P935-944, May 2024



crisaborole ointment, 2% for stasis dermatitis


- ▶ **Randomized, proof-of-concept phase 2a study**
- ▶ Volume 90, ISSUE 5, P945-952, May 2024



Roflumilast foam 0.3% for seborrheic dermatitis

A randomized, double-blinded, vehicle-controlled, phase 3 trial

- ▶ 79.5% of roflumilast-treated and 58.0% of vehicle-treated patients met the primary endpoint ($P < .001$);
- ▶ [Volume 90, ISSUE 5, P986-993, May 2024](#)



Generalized pustular psoriasis

- ▶ The IL-36R antagonist spesolimab rapidly controls GPP flares and prevents recurrence
- ▶ Phase II trial of imsidolimab, a humanized IgG4 monoclonal antibody specifically binding IL-36R, demonstrated rapid resolution
- ▶ [Volume 90, ISSUE 4, P727-730, April 2024](#); [Volume 90, ISSUE 4, P705-706, April 2024](#)



Generalized pustular psoriasis

- ▶ **Consensus statement from the National Psoriasis Foundation**
- ▶ **Letter from the editor: Avoiding delays in emergent treatment of generalized pustular psoriasis**
- ▶ Volume 90, ISSUE 4, P727-730, April 2024; Volume 90, ISSUE 4, P705-706, April 2024



Histopathologic regression in patients with primary cutaneous melanoma

- ▶ Favorable survival and progression-free survival on immune checkpoint inhibitor therapy

- ▶ Volume 90, ISSUE 4, P739-748, April 2024



Incidence of skin cancers following ultraviolet phototherapy without psoralens

- ▶ No increased risk of melanoma and keratinocyte cancer was found with phototherapy.

▶ Volume 90, ISSUE 4, P759-766, April 2024



Noninvasive treatment of cutaneous neurofibromas

- ▶ Radiofrequency (RF) needle coagulation, 755 nm alexandrite laser with suction, 980 nm diode laser, and intratumoral injection of 10 mg/mL deoxycholate
- ▶ Each modality significantly ($P < .05$) reduced or cleared cNFs
- ▶ Alexandrite laser and deoxycholate were fast and least painful
- ▶ 980 nm laser was most painful
- ▶ Volume 90, ISSUE 4, P767-774, April 2024



Deucravacitinib in scalp psoriasis

► Effective and well tolerated

► Volume 90, ISSUE 4, P775-782, April 2024



Optimal time to discontinue propranolol in infantile hemangiomas

- ▶ Patient is aged >13 months
 - ▶ and the lesion has maintained for 3 months after reaching maximum regression

▶ Volume 90, ISSUE 4, P783-789, April 2024



EGFR receptor antagonists

- ▶ Zinc supplementation is associated with improvement in hand-foot skin reaction in patients on vascular endothelial growth factor receptor-tyrosine kinase inhibitors

- ▶ Volume 90, ISSUE 4, P814-815, April 2024



Impact of dupilumab on patch testing

- ▶ Majority still meaningful
- ▶ 1230 paired allergens
 - ▶ 1022 were the same
 - ▶ 34 were positive
 - ▶ 44 were lost

▶ Volume 90, ISSUE 3, P512-520, March 2024



Eblasakimab (IL-13) for atopic dermatitis, phase 1b

- ▶ EASI -65% vs -27%, $P = .014$
- ▶ Volume 90, ISSUE 3, P504-511, March 2024



Apremilast for genital psoriasis

- ▶ At Week 16, 39.6% vs 19.5% achieved ≥ 2 -point reduction in PGA score
- ▶ Volume 90, ISSUE 3, P485-493, March 2024



Orismilast in moderate-to-severe psoriasis



- ▶ PDE4 inhibition
- ▶ % change in PASI, from baseline to week 16 (orismilast –52.6% to –63.7% and placebo, –17.3%; all $P < .001$).
- ▶ Greater proportions receiving orismilast achieved PASI75 (39.5%-49.0% vs 6.5%) ; $P < .05$
- ▶ PASI90 (22.0%-28.3% vs 8.3%) ; $P < .05$ for 20 and 40 mg
- ▶ Volume 90, ISSUE 3, P494-503, March 2024

Povorcitinib for HS, phase 2 study

- ▶ Week 16 (15 mg, 48.1%, $P = .0445$; 45 mg, 44.2%, $P = .0998$; 75 mg, 45.3%, $P = .0829$) versus placebo (28.8%).
- ▶ A total of 60.0% and 65.4% of povorcitinib- and placebo-treated patients had adverse events.
- ▶ Volume 90, ISSUE 3, P521-529, March 2024



Organic solvent exposure and systemic sclerosis

► Volume 90, ISSUE 3, P605-607, March 2024



Hyperbaric oxygen therapy for the treatment of calciphylaxis

- ▶ Retrospective study
- ▶ Univariate survival analyses showed that full HBOT treatment was associated with significantly ($P = .016$) longer survival time.
- ▶ Increasing number of HBOT sessions was associated with improved mortality outcomes, with 1, 5, 10 and 20 sessions yielding decreasing hazard ratios. T
- ▶ here was also a significant ($P = .042$) positive association between increasing number of HBOT sessions and increased wound score.
- ▶ Volume 90, ISSUE 1, P45-51, January 2024



Dermatoscopic perifollicular linear projections: lentigo maligna

- ▶ 83 consecutive LMs, 21/83 (25.3%) displayed “bulging of hair follicles” on reflectance confocal microscopy
- ▶ 18 of these 21 (85.7%), displayed PLP on dermatoscopy.
- ▶ From a database of 2873 consecutively imaged and biopsied lesions, 252 flat-pigmented facial lesions were included. PLP was seen in 47/76 melanomas (61.8%), compared with 7/176 lesions (3.9%) with other diagnosis ($P < .001$).
- ▶ The sensitivity was 61.8% (95% CI, 49.9%-72.7%), specificity 96.0% (95% CI, 92.9%-98.4%).
- ▶ PLP was independently associated with LM diagnosis on multivariate analysis (OR 26.1 [95% CI, 9.6%-71.0]).
- ▶ Volume 90, ISSUE 1, P52-57, January 2024



Excision vs topical 5% 5-fluorouracil and PDT for Bowen's disease


- ▶ **Multicenter randomized controlled trial**
- ▶ Sustained clearance was 97.4% (75/77) after excision, 85.7% (66/77) after 5-fluorouracil, and 82.1% (64/78) after MAL-PDT.

▶ Volume 90, ISSUE 1, P58-65, January 2024




Extramammary Paget's disease

- ▶ 249 patients with a median follow-up of 60 months
- ▶ The 5-year recurrence-free survival after Mohs micrographic surgery (MMS), WLE with tumor-free margins, WLE with positive margins, radiotherapy, and topical treatments was 63.0%, 51.4%, 20.4%, 30.1%, and 20.8%, respectively.
- ▶ Volume 90, ISSUE 1, P66-73, January 2024



Cutaneous granulomas associated with rubella virus

- ▶ Immunocompromised and immunocompetent patients
- ▶ Volume 90, ISSUE 1, P111-121, January 2024



Modified red light PDT vs low-dose isotretinoin for moderate to severe acne vulgaris

- ▶ **A prospective, randomized, multicenter study**
- ▶ M-PDT offers a more rapid onset of improvement, comparable overall efficacy, good tolerability, and comparable durability of response compared with ISO
- ▶ Volume 89, ISSUE 6, P1141-1148, December 2023



1726 nm laser for moderate-to-severe acne

- ▶ Well tolerated with durable progressive posttreatment improvement to at least 26 weeks for moderate-to-severe acne across skin types
- ▶ Volume 89, ISSUE 4, P703-710, October 2023



Microencapsulated benzoyl peroxide and tretinoin for acne vulgaris

► Effective and well tolerated

► Volume 89, ISSUE 4, P719-727, October 2023



Photodynamic therapy versus minocycline for moderate-to-severe rosacea

- ▶ ALA-PDT can improve rosacea mainly in papulopustular lesions

- ▶ Volume 89, ISSUE 4, P711-718, October 2023





Adalimumab plus surgery vs adalimumab monotherapy for hidradenitis suppurativa

VOLUME 89, ISSUE 4, P677-684, OCTOBER 2023

Alpha-gal syndrome

- ▶ Red meat allergy after *Amblyoma* tick bites
- ▶ Volume 89, ISSUE 4, P750-757, October 2023



Cross-reactions with biologics

- ▶ **Cetuximab** - targets EGFR, used colorectal and head and neck cancer.
- ▶ α -Gal present on the mouse-derived Fab portion of the heavy chain.
- ▶ Alpha-gal-containing biologics and anaphylaxis
- ▶ Allergol Int. 2019 Jul;68(3):296-300.

